AI use case

AI-Driven Antiviral Drug Development

Exscientia developed AI-driven solutions for antiviral drug discovery, particularly demonstrated during the COVID-19 pandemic. The company received funding from the COVID-19 The…

Browse catalog

At a glance

Core facts from this catalog record. Primary narrative lives in the hero above; full raw fields follow in the next section.

Company/Organization: Gilead Sciences
Industry: Biotechnology
Location: Oxford

Record fields

Every column from the source row, in stable order. URLs open in a new tab.

Title

AI-Driven Antiviral Drug Development

Content

Exscientia developed AI-driven solutions for antiviral drug discovery, particularly demonstrated during the COVID-19 pandemic. The company received funding from the COVID-19 Therapeutics Accelerator (backed by the Gates Foundation, Wellcome, and Mastercard) to design virus protease inhibitors using their AI platform. Exscientia's approach delivered optimized compounds fulfilling complex design goals faster and more effectively than conventional methods. The AI platform's ability to process vast chemical spaces enabled rapid identification of antiviral candidates. Beyond COVID-19, Exscientia applied similar AI approaches to other viral diseases including those affecting respiratory systems. Note: Exscientia merged with Recursion in 2024, combining two leading AI drug discovery companies.

URL

https://www.businesswire.com/news/home/20210513005059/en/Exscientia-Announces-Second-Molecule-Created-Using-AI-From-Sumitomo-Dainippon-Pharma-Collaboration-to-Enter-Phase-1-Clinical-Trial

Continue exploring AI deployments in the catalog.

Back to use cases